<DOC>
	<DOCNO>NCT02905214</DOCNO>
	<brief_summary>Postmarket surveillance term safety efficacy Sirolimus-eluting Coroflex ISAR Stent treatment `` real world '' patient de-novo restenotic lesion stand-alone angioplasty coronary artery .</brief_summary>
	<brief_title>Coroflex ISAR 2000 Extended Registry ( ISAR2000 Extended )</brief_title>
	<detailed_description>The aim study assess safety efficacy elective deployment Sirolimus-eluting Coroflex ISAR Stent treatment `` real world '' de-novo restenotic lesion stand-alone angioplasty coronary artery 2.0 mm 4.0 mm diameter 30 mm length procedural success preservation vessel patency .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>patient suitable percutaneous coronary intervention proof ischemia least 18 year age Intolerance sirolimus and/or probucol Allergy component coat Pregnancy lactation Complete occlusion treatment vessel Severely calcified stenosis Cardiogenic shock Risk intraluminal thrombus Haemorrhagic diathesis another disorder gastrointestinal ulceration cerebral circulatory disorder restrict use platelet aggregation inhibitor therapy anticoagulation therapy Surgery shortly myocardial infarction indication thrombus poor coronary flow behavior Severe allergy contrast medium Lesions untreatable PTCA interventional technique Patients ejection fraction &lt; 30 % Vascular reference diameter &lt; 2.00 mm Treatment leave stem ( first section leave coronary artery ) Indication bypass surgery Contraindication whichever accompany medication necessary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>